Dr. Sherry Gu serves as Executive Vice President and Chief Technology Officer at WuXi Biologics, where she leads Biologics Development — a world's leading technology and capability platform for biologics CMC development and clinical manufacturing with proven 6-month DNA-to-IND capability. With 29+ years of biopharmaceutical expertise, she has directly led numerous early- and late-stage CMC projects, including DNA to EUA approval of Sotrovimab through the VIR-GSK collaboration in the combat of the worldwide COVID-19 pandemic. Before joining WuXi Biologics, she held leadership roles at Eli Lilly and Company and Bristol Myers Squibb. She holds a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology (MIT).